LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

Authors :: Mario Mandalà
V. Chiarion Sileni
Piotr Rutkowski
Nuhad K. Ibrahim
Ke Chen
F. De Galitiis
P.A. Ascierto
John M. Kirkwood
Georgina V. Long
Dirk Schadendorf
M. Del Vecchio
Sama Ahsan
Jason J. Luke
Muhammad A. Khattak
Jacek Mackiewicz
Vernon K. Sondak
L. De La Cruz Merino
Richard A. Scolyer
Paola Queirolo
Alexander M.M. Eggermont
Source :: Annals of Oncology. 32:S1314-S1315
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Double blind
medicine.medical_specialty
Oncology
business.industry
Stage II melanoma
medicine
Hematology
Pembrolizumab
Placebo
business
Complete resection
Surgery

Full Text Access

Tools